Dan Dolan | Chief Financial Officer |
Ted Schroeder | Chief Executive Officer |
Christine Guico-Pabia | Chief Medical Officer |
Carl Byrnes | Northland Capital Markets |
Thomas Yip | HC Wainwright |
Good afternoon, ladies and gentlemen, and welcome to the Nabriva Therapeutics First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.
As a reminder, this conference call is being recorded. I would now like to turn the call over to Dan Dolan, Nabriva’s Chief Financial Officer.